Bachem Valuation Multiples

Bachem Overview

About Bachem

Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. It has two geographic segments Europe/Asia and USA. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities.

Founded

1971

HQ

Employees

2.2K

Website

bachem.com

Sectors

BiopharmaceuticalsChemicalsBioTech

Financials (LTM)

Revenue: $985M

EBITDA: $301M

EV

$7B

Valuation Multiples

Multiples.vc

Start free trial

Bachem Financials

Bachem reported last 12-month revenue of $985M and EBITDA of $301M.

In the same LTM period, Bachem generated $285M in gross profit, $301M in EBITDA, and $201M in net income.

Bachem P&L

In the most recent fiscal year, Bachem reported revenue of $887M and EBITDA of $274M.

Bachem expects next 12-month revenue of XXX and NTM EBITDA of XXX

Bachem Stock Performance

Bachem has current market cap of $7B, and enterprise value of $7B.

Bachem's stock price is $89.57.

Bachem Valuation Multiples

Bachem trades at 6.7x EV/Revenue multiple, and 21.9x EV/EBITDA.

Bachem Financial Valuation Multiples

As of April 18, 2026, Bachem has market cap of $7B and EV of $7B.

Equity research analysts estimate Bachem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Bachem has a P/E ratio of 33.4x.

Bachem Margins & Growth Rates

Bachem's revenue in the last 12 month grew by 32%.

Bachem's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.0M for the same period.

Bachem's rule of 40 is 67% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Bachem's rule of X is 124% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Bachem Public Comps

See public comps and valuation multiples for other Biopharmaceuticals and Chemicals comps.

Bachem M&A Activity

Bachem acquired XXX companies to date.

Last acquisition by Bachem was on XXXXXXXX, XXXXX. Bachem acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Bachem Investment Activity

Bachem invested in XXX companies to date.

Bachem made its latest investment on XXXXXXXX, XXXXX. Bachem invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).